CA2569915A1 — D-xylopyranosyl-substituted phenyls, medicaments containing said compounds, the use thereof, and methods for producing the same
Assigned to Boehringer Ingelheim International GmbH · Expires 2006-01-12 · 20y expired
What this patent protects
The invention relates to D-xylopyranosyl-substituted phenyls of general formula (I) wherein the radicals R1 to R5, X, Z and R7a, R7b, R7c have the designations cited in patent claim 1, said phenyls having an inhibiting effect on the sodium-dependent glucose cotransporter SGLT. Th…
USPTO Abstract
The invention relates to D-xylopyranosyl-substituted phenyls of general formula (I) wherein the radicals R1 to R5, X, Z and R7a, R7b, R7c have the designations cited in patent claim 1, said phenyls having an inhibiting effect on the sodium-dependent glucose cotransporter SGLT. The invention also relates to medicaments for treating metabolic diseases.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.